(XPEV) Xpeng - Ratings and Ratios
Electric, Sedan, SUV, MPV, Platform
XPEV EPS (Earnings per Share)
XPEV Revenue
Description: XPEV Xpeng October 16, 2025
XPeng Inc. (NYSE:XPEV) designs, develops, manufactures, and markets a portfolio of smart electric vehicles (EVs) in China, including the P7/P7i sports sedan, G9 and G6 SUVs, X9 seven-seater MPV, MONA M03 hatchback coupe, and the performance-oriented P7+. The firm also supplies its proprietary XOS Tianji in-car operating system, the SEPA 2.0 electric platform, and a suite of ancillary services such as supercharging, maintenance, insurance tech, and auto-financing.
Recent data (Q3 2024) show XPeng delivered roughly 38,000 vehicles, a year-over-year increase of about 30 % and the strongest growth among domestic EV makers, while R&D spending rose to ~4.5 billion RMB, reflecting its push on autonomous driving and battery-efficiency technologies. The Chinese EV market is expanding at ~20 % CAGR, but the pace of government subsidies is tapering, making cost-competitiveness and software differentiation increasingly critical for market share.
For a deeper, data-driven assessment of XPeng’s valuation dynamics-including forward-looking cash-flow models and scenario analysis-consider exploring the detailed analyst toolkit on ValueRay.
XPEV Stock Overview
| Market Cap in USD | 21,320m |
| Sub-Industry | Automobile Manufacturers |
| IPO / Inception | 2020-08-27 |
XPEV Stock Ratings
| Growth Rating | 50.9% |
| Fundamental | 39.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 66.0% |
| Analyst Rating | 4.21 of 5 |
XPEV Dividends
Currently no dividends paidXPEV Growth Ratios
| Growth Correlation 3m | 66.9% |
| Growth Correlation 12m | 73.3% |
| Growth Correlation 5y | -58.9% |
| CAGR 5y | 37.80% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.53 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.10 |
| Sharpe Ratio 12m | 0.52 |
| Alpha | 69.36 |
| Beta | 2.531 |
| Volatility | 62.04% |
| Current Volume | 4323.6k |
| Average Volume 20d | 6493.6k |
| Stop Loss | 20.1 (-5.4%) |
| Signal | -0.07 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-4.28b TTM) > 0 and > 6% of Revenue (6% = 3.62b TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA -4.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.29% (prev 41.22%; Δ -29.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.02 (>3.0%) and CFO -2.01b > Net Income -4.28b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (951.2m) change vs 12m ago -49.62% (target <= -2.0% for YES) |
| Gross Margin 15.75% (prev 7.07%; Δ 8.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 72.02% (prev 48.32%; Δ 23.70pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -9.84 (EBITDA TTM -2.78b / Interest Expense TTM 537.3m) >= 6 (WARN >= 3) |
Altman Z'' -2.13
| (A) 0.07 = (Total Current Assets 54.77b - Total Current Liabilities 47.96b) / Total Assets 92.43b |
| (B) -0.46 = Retained Earnings (Balance) -42.74b / Total Assets 92.43b |
| (C) -0.06 = EBIT TTM -5.28b / Avg Total Assets 83.71b |
| (D) -0.65 = Book Value of Equity -40.58b / Total Liabilities 62.09b |
| Total Rating: -2.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 39.67
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield -2.99% = -1.49 |
| 3. FCF Margin -7.36% = -2.76 |
| 4. Debt/Equity 1.01 = 2.01 |
| 5. Debt/Ebitda -4.27 = -2.50 |
| 6. ROIC - WACC (= -23.84)% = -12.50 |
| 7. RoE -13.77% = -2.29 |
| 8. Rev. Trend 83.40% = 6.26 |
| 9. EPS Trend 89.08% = 4.45 |
What is the price of XPEV shares?
Over the past week, the price has changed by -1.85%, over one month by -0.56%, over three months by +12.56% and over the past year by +92.39%.
Is Xpeng a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XPEV is around 18.97 USD . This means that XPEV is currently overvalued and has a potential downside of -10.69%.
Is XPEV a buy, sell or hold?
- Strong Buy: 14
- Buy: 7
- Hold: 6
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the XPEV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.4 | 24.2% |
| Analysts Target Price | 26.4 | 24.2% |
| ValueRay Target Price | 22 | 3.4% |
XPEV Fundamental Data Overview October 13, 2025
P/E Forward = 59.8802
P/S = 0.3536
P/B = 5.3256
Beta = 2.531
Revenue TTM = 60.29b CNY
EBIT TTM = -5.28b CNY
EBITDA TTM = -2.78b CNY
Long Term Debt = 5.79b CNY (from longTermDebt, last quarter)
Short Term Debt = 19.67b CNY (from shortTermDebt, last quarter)
Debt = 30.67b CNY (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.86b CNY (from netDebt column, last quarter)
Enterprise Value = 148.60b CNY (151.80b + Debt 30.67b - CCE 33.87b)
Interest Coverage Ratio = -9.84 (Ebit TTM -5.28b / Interest Expense TTM 537.3m)
FCF Yield = -2.99% (FCF TTM -4.44b / Enterprise Value 148.60b)
FCF Margin = -7.36% (FCF TTM -4.44b / Revenue TTM 60.29b)
Net Margin = -7.10% (Net Income TTM -4.28b / Revenue TTM 60.29b)
Gross Margin = 15.75% ((Revenue TTM 60.29b - Cost of Revenue TTM 50.80b) / Revenue TTM)
Gross Margin QoQ = 17.33% (prev 15.56%)
Tobins Q-Ratio = 1.61 (Enterprise Value 148.60b / Total Assets 92.43b)
Interest Expense / Debt = 0.25% (Interest Expense 75.2m / Debt 30.67b)
Taxrate = 1.93% (-9.42m / -487.2m)
NOPAT = -5.18b (EBIT -5.28b * (1 - 1.93%)) [loss with tax shield]
Current Ratio = 1.14 (Total Current Assets 54.77b / Total Current Liabilities 47.96b)
Debt / Equity = 1.01 (Debt 30.67b / totalStockholderEquity, last quarter 30.34b)
Debt / EBITDA = -4.27 (negative EBITDA) (Net Debt 11.86b / EBITDA -2.78b)
Debt / FCF = -2.67 (negative FCF - burning cash) (Net Debt 11.86b / FCF TTM -4.44b)
Total Stockholder Equity = 31.09b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.63% (Net Income -4.28b / Total Assets 92.43b)
RoE = -13.77% (Net Income TTM -4.28b / Total Stockholder Equity 31.09b)
RoCE = -14.33% (EBIT -5.28b / Capital Employed (Equity 31.09b + L.T.Debt 5.79b))
RoIC = -11.04% (negative operating profit) (NOPAT -5.18b / Invested Capital 46.93b)
WACC = 12.80% (E(151.80b)/V(182.47b) * Re(15.34%) + D(30.67b)/V(182.47b) * Rd(0.25%) * (1-Tc(0.02)))
Discount Rate = 15.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -28.65%
Fair Price DCF = unknown (Cash Flow -4.44b)
EPS Correlation: 89.08 | EPS CAGR: 38.91% | SUE: 0.67 | # QB: 0
Revenue Correlation: 83.40 | Revenue CAGR: 43.08% | SUE: 0.04 | # QB: 0
Additional Sources for XPEV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle